<DOC>
	<DOCNO>NCT02153489</DOCNO>
	<brief_summary>The purpose study assess effect aclidinium bromide compare placebo improve dilatation airway ( bronchodilation ) , symptoms chronic obstructive pulmonary disease ( COPD ) , sleep quality physical activity 3 week treatment aclidinium bromide 400 μg administer twice daily patient stable moderate-and-severe COPD .</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled , Crossover Study Assess Effect Aclidinium Bromide 400 μg Bid COPD Symptoms Sleep Quality After 3 Weeks Treatment Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male nonpregnant , nonlactating female age ≥40 year . Women childbearing potential follow specific study requirement ( negative serum pregnancy test Screening Visit use , last two month Screening Visit , least one medically approve highly effective method birth control Current excigarette smoker ( patient quit smoke 6 month prior Screening Visit ) , smoke history least 10 packyears . Patients clinical diagnosis chronic obstructive pulmonary disease ( COPD ) accord GOLD guideline 2013 , post bronchodilator FEV1 &lt; 80 % , FEV1 ≥ 40 % Screening Visit Patients must able perform repeatable pulmonary function test FEV1 accord American Thoracic Society [ ATS ] /European Respiratory Society [ ERS ] 2005 criterion Screening Visit Patients eligible able participate study consent write purpose nature investigation explain History current diagnosis asthma Patients moderate severe sleep apnoea assess screen Patients develop respiratory tract infection COPD exacerbation within 6 week ( 3 month hospitalisation require ) Screening Visit ( Visit 1 ) runin period Clinically significant respiratory condition Patients Type I uncontrolled Type II diabetes , uncontrolled hypoor hyperthyroidism , hypokalaemia , hyperadrenergic state , uncontrolled untreated hypertension Patients may need start pulmonary rehabilitation program study and/or patient started/finished within 3 month prior Screening Visit Use longterm oxygen therapy ( 15 hours/day ) Patients maintain regular day/night , waking/sleeping cycle include night shift worker Clinically significant cardiovascular condition QTc &gt; 470 millisecond manual ECG reading perform Screening Visit Patients clinically relevant abnormality opinion investigator Screening Visit ( Visit 1 ) result clinical laboratory test , ECG parameters physical examination ) Patients history hypersensitivity reaction inhale anticholinergic , long short act β2agonists , sympathomimetic amine , inhaled medication component ( include report paradoxical bronchospasm ) Patients known narrowangle glaucoma , symptomatic bladder neck obstruction , acute urinary retention , patient symptomatic nonstable prostatic hypertrophy Patients know noncontrolled history human immunodeficiency virus ( HIV ) infection and/or active hepatitis History malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year basal squamous cell skin cancer Patients serious uncontrolled physical mental dysfunction , moderatetosevere depression , confirm Beck Depression Inventory ( BDIII ) total score &gt; 28 . Patients history ( within 2 year prior Screening Visit ) drug and/or alcohol abuse may prevent study compliance base investigator judgment Patients unlikely cooperative ca n't comply study procedure . Patients treat investigational drug within 30 day ( 6 halflives , whichever long ) prior Screening Visit Patients intend use concomitant medication permit protocol undergone require stabilization period prohibit medication Any condition , investigator 's opinion , might indicate patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>